Please login to the form below

Not currently logged in
Email:
Password:

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics

Versartis has named Joshua Brumm as its first chief financial officer.

Brumm joins from Pharmacyclics where he was principal financial officer and executive VP of finance.

He already has life sciences financial experience, having previously served as chief financial officer for Zeltiq Aesthetics and director of finance at Proteolix.

In his new role at Versartis, Brumm will lead the company's financial operations as it prepares to for the commercialisation of its phase III prospect VRS-317, which is in development as a treatment for growth hormone deficiency.

The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."

18th December 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics